Variation in ACE2 levels are not related to outcomes from COVID-19
1 August 2021. Related: COVID-19: pathogenesis, COVID-19.
COVID-19
London HIV study of responses to COVID-19 vaccines and natural infection (SCAPE)
1 July 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19: research studies, COVID-19.
mRNA vaccine fails to produce antibody response in late-stage HIV: low CD4 count and high viral load
1 July 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Special report on background incidence of adverse events in vaccine studies
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
Third vaccine dose increases immune response to 68% in French transplant recipients
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
Third COVID-19 vaccine dose in US cohort of people on immune-suppressing treatment: safety and ethical issues
1 July 2021. Related: COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
Plans for universal third vaccine dose for UK adults from September
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccines increase sperm quality: potential to help uptake
1 July 2021. Related: COVID-19: vaccine research, COVID-19.
Research approach to rapidly review candidate treatments for COVID-19: nine studies using ACTIV protocol
1 July 2021. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.
COVID-19 treatment: tofacitinib, REGN bNAbs, convalescent plasma
1 July 2021. Related: COVID-19: investigational drugs, COVID-19.
Virology Education: monthly forums on COVID-19
1 July 2021. Related: COVID-19: on the web, COVID-19.
COVID-19 timeline: global events from the last 18 months
1 July 2021. Related: COVID-19: on the web, COVID-19.
COVIDsalon
1 July 2021. Related: COVID-19: on the web, COVID-19.
Selected presentations at BHIVA: COVID-19, PrEP in the UK, community involvement and more…
1 June 2021. Related: Conference reports, COVID-19: transmission & prevention, COVID-19.
No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19
1 June 2021. Related: Conference reports, Pregnancy, COVID-19: pathogenesis, COVID-19.
HIV associated with higher risk of severe COVID-19 in US cohort
1 June 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
MHRA authorises Janssen/J&J COVID-19 vaccination in the UK
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Reduced antibody responses to first dose of mRNA COVID-19 vaccines in HIV positive people with a lower CD4 count
1 June 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
France routinely recommends third dose of COVID-19 vaccine for some people with reduced immune function
1 June 2021. Related: COVID-19: vaccine research, COVID-19: guidelines, COVID-19.
US CDC reports 10,000 breakthrough infections after full vaccination: showing success of vaccine programme
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Cases of COVID-19 reported including deaths in care home residents after full-course vaccination
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Israeli study reports reduced vaccine efficacy in people with immune suppression until 14 days after the second dose
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Novavax reports 43% efficacy against B.1.351 South African variant but negative impact in HIV positive participants
1 June 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Oxford/AZ vaccine linked to 242 rare bloods clots in the UK: alternative recommended for people younger than 40
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccine candidate from GSK and Sanofi to move to phase 3 placebo controlled study
1 June 2021. Related: COVID-19: vaccine research, COVID-19.
Meta-analysis of 18 ivermectin studies
1 June 2021. Related: COVID-19: treatment access, COVID-19.
Asymptomatic infection has similar SARS-CoV-2 viral load to mild COVID-19
1 June 2021. Related: COVID-19: transmission & prevention, COVID-19.
Missed TB diagnoses during COVID-19 outbreaks despite prolonged respiratory symptoms
1 June 2021. Related: COVID-19: complications, COVID-19.
Correlation between COVID-19 severity and immune responses after six months
1 June 2021. Related: COVID-19: pathogenesis, COVID-19: transmission & prevention, COVID-19.
Durable antibody responses 9 months after exposure irrespective of symptoms: broader vaccine coverage still needed to reach herd immunity
1 June 2021. Related: COVID-19: pathogenesis, COVID-19: transmission & prevention, COVID-19.
BHIVA registry reports HIV is independently linked to worse presentation and outcomes from COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
HIV is linked to higher mortality from COVID-19 compared to HIV negative: 60% of deaths were black ethnicity
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Case-control study of HIV positive people hospitalised with COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
US CDC includes HIV as medical criteria for priority to COVID-19 vaccines
3 May 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: guidelines, COVID-19.
Review of research into SARS-CoV-2 and HIV coinfection
3 May 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Similar immune responses to the Oxford/AZ COVID vaccine reported In HIV positive people with high CD4 counts
3 May 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19.
Low responses to mRNA COVID-19 vaccines in those older than 80 vs <60 years and in recipients of solid organ transplants
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Two cases of viral breakthrough infections despite full protection from Pfizer mRNA vaccination
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
US post-authorisation safety data on Pfizer and Moderna vaccines
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
EMA review of Oxford/AZ vaccine and rare blood clots reported in the EU
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Interim results report 80% efficacy for India’s COVAXIN vaccine
3 May 2021. Related: COVID-19: vaccine research, COVID-19.
Three new COVID-19 vaccine studies enrolling in the UK
3 May 2021. Related: COVID-19: vaccine research, COVID-19: research studies, COVID-19.
Dexamethasone: final results from RECOVERY study
3 May 2021. Related: COVID-19: investigational drugs, COVID-19.
No impact from anakinra in mild/moderate COVID-19 pneumonia
3 May 2021. Related: COVID-19: investigational drugs, COVID-19.
Bar opening in the US: 100 guests linked to at least 46 cases of COVID-19
3 May 2021. Related: COVID-19: transmission & prevention, COVID-19.
Long COVID: studies reporting on long-term follow up on COVID-19
3 May 2021. Related: COVID-19: long COVID, COVID-19: pathogenesis, COVID-19.
Large sporting event in US linked to 649 cases of COVID-19
3 May 2021. Related: COVID-19: transmission & prevention, COVID-19.
Three carefully documented cases of SARS-CoV-2 transmission in a hospital setting despite masks
3 May 2021. Related: COVID-19: transmission & prevention, COVID-19.
CROI 2021: New compounds for prevention and treatment of COVID-19
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
BHIVA guidelines on COVID-19 vaccines and people living with HIV: DRAFT online for comment
1 April 2021. Related: Guidelines, COVID-19: guidelines, COVID-19.
BHIVA advice on access to COVID-19 vaccines and shielding in the UK
1 April 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
US phase 3 results enable FDA review of the Oxford/AstraZeneca vaccine
1 April 2021. Related: COVID-19: vaccine research, COVID-19.
CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
Janssen/J&J vaccine against COVID-19 is approved in the EU
12 March 2021. Related: COVID-19: vaccine research, COVID-19.
Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
HIV positive people in the UK now elligible for COVID vaccinations – and to become available at HIV clinics
24 February 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
What are the main COVID-19 variants? How can they affect vaccine responses?
24 February 2021. Related: COVID-19: vaccine research, COVID-19: transmission & prevention, COVID-19.
Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose
24 February 2021. Related: COVID-19: vaccine research, COVID-19.